CN101100480A - 新颖的依托孕烯酯 - Google Patents

新颖的依托孕烯酯 Download PDF

Info

Publication number
CN101100480A
CN101100480A CNA2007101028610A CN200710102861A CN101100480A CN 101100480 A CN101100480 A CN 101100480A CN A2007101028610 A CNA2007101028610 A CN A2007101028610A CN 200710102861 A CN200710102861 A CN 200710102861A CN 101100480 A CN101100480 A CN 101100480A
Authority
CN
China
Prior art keywords
etonogestrel
female
male
esters
undecanoate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007101028610A
Other languages
English (en)
Chinese (zh)
Inventor
H·德尼因斯
H·A·A·万德福尔特
D·莱森
A·J·格罗滕胡伊斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Organon NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon NV filed Critical Organon NV
Publication of CN101100480A publication Critical patent/CN101100480A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2007101028610A 2002-05-30 2003-05-22 新颖的依托孕烯酯 Pending CN101100480A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02077119.2 2002-05-30
EP02077119 2002-05-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB038123754A Division CN1314701C (zh) 2002-05-30 2003-05-22 依托孕烯酯

Publications (1)

Publication Number Publication Date
CN101100480A true CN101100480A (zh) 2008-01-09

Family

ID=29595014

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2007101028610A Pending CN101100480A (zh) 2002-05-30 2003-05-22 新颖的依托孕烯酯
CNB038123754A Expired - Fee Related CN1314701C (zh) 2002-05-30 2003-05-22 依托孕烯酯

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB038123754A Expired - Fee Related CN1314701C (zh) 2002-05-30 2003-05-22 依托孕烯酯

Country Status (30)

Country Link
US (1) US7323454B2 (enExample)
EP (1) EP1513861B1 (enExample)
JP (1) JP4716726B2 (enExample)
KR (1) KR20050009723A (enExample)
CN (2) CN101100480A (enExample)
AR (1) AR040130A1 (enExample)
AT (1) ATE349458T1 (enExample)
AU (1) AU2003238081B2 (enExample)
BR (1) BR0311254A (enExample)
CA (1) CA2487722C (enExample)
CO (1) CO5631449A2 (enExample)
DE (1) DE60310714T2 (enExample)
DK (1) DK1513861T3 (enExample)
ES (1) ES2277085T3 (enExample)
HR (1) HRP20041101A2 (enExample)
IL (1) IL165087A0 (enExample)
IS (1) IS2421B (enExample)
MX (1) MXPA04011797A (enExample)
NO (1) NO20044898L (enExample)
NZ (1) NZ536619A (enExample)
PE (1) PE20040068A1 (enExample)
PL (1) PL373855A1 (enExample)
PT (1) PT1513861E (enExample)
RS (1) RS97604A (enExample)
RU (1) RU2325910C2 (enExample)
SI (1) SI1513861T1 (enExample)
TW (1) TW200403065A (enExample)
UA (1) UA80126C2 (enExample)
WO (1) WO2003102012A2 (enExample)
ZA (1) ZA200410410B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200400041A (en) * 2002-05-30 2004-01-01 Akzo Nobel Nv Use of new etonogestrel esters
JP5756588B2 (ja) 2005-07-15 2015-07-29 ミセル テクノロジーズ、インコーポレイテッド 制御されたモルホロジーの薬剤粉末を含むポリマーコーティング
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
CA2996768C (en) 2006-04-26 2020-12-08 Micell Technologies, Inc. Coatings containing multiple drugs
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
JP5603598B2 (ja) 2007-01-08 2014-10-08 ミセル テクノロジーズ、インコーポレイテッド 生物分解層を有するステント
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
BRPI0910969B8 (pt) 2008-04-17 2021-06-22 Micell Technologies Inc dispositivo
WO2011009096A1 (en) 2009-07-16 2011-01-20 Micell Technologies, Inc. Drug delivery medical device
EP2313122B1 (en) 2008-07-17 2019-03-06 Micell Technologies, Inc. Drug delivery medical device
EP2411083A4 (en) 2009-03-23 2013-11-13 Micell Technologies Inc MEDICAL ACTIVE COMPOSITION DEVICE
EP2413847A4 (en) 2009-04-01 2013-11-27 Micell Technologies Inc COATED STENTS
EP2531140B1 (en) 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
WO2011133655A1 (en) 2010-04-22 2011-10-27 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
EP2593039B1 (en) 2010-07-16 2022-11-30 Micell Technologies, Inc. Drug delivery medical device
WO2013012689A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
JP6330024B2 (ja) 2013-03-12 2018-05-23 マイセル・テクノロジーズ，インコーポレイテッド 生体吸収性バイオメディカルインプラント
JP2016519965A (ja) 2013-05-15 2016-07-11 マイセル・テクノロジーズ，インコーポレイテッド 生体吸収性バイオメディカルインプラント
RU2595818C1 (ru) * 2015-05-25 2016-08-27 Федеральное государственное бюджетное научное учреждение "Научный центр проблем здоровья семьи и репродукции человека" Способ комплексного лечения дисфункции яичников при применении гормонального контрацептива имплантата "импланона"
CN111057120B (zh) * 2019-12-27 2021-04-27 苏州翔实医药发展有限公司 一种依托孕烯衍生物a及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1013284B (de) 1956-03-22 1957-08-08 Schering Ag Verfahren zur Einfuehrung der Reste wenig reaktionsfaehiger Carbonsaeuren, insbesondere des ª‰-Cyclopentyl-propionylrestes, in die 17ª‡-staendige Oxygruppe solcher Steroide, die am Kohlenstoffatom 17 neben der Oxygruppe eine Acetylgruppe tragen
GB845442A (en) 1956-03-22 1960-08-24 Schering Ag Manufacture of steroid compounds
GB8313921D0 (en) * 1983-05-19 1983-06-22 World Health Org Contraceptive compositions
DE4227989A1 (de) 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DE4240806A1 (de) 1992-12-01 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol
JPH07101884A (ja) 1993-10-01 1995-04-18 Sanei Gen F F I Inc 水溶性ヘミセルロースを含有する製剤
FI962618A7 (fi) * 1993-12-27 1996-06-25 Akzo Nobel Nv Perkutaanisesti absorboituva valmiste
WO1997003709A1 (de) 1995-07-17 1997-02-06 Schering Aktiengesellschaft Mittel zur transdermalen applikation enthaltend ester des 3-ketodegestrel
DE19613698A1 (de) 1995-07-17 1997-01-23 Schering Ag Mittel zur transdermalen Applikation enthaltend Ester des 13-Ethyl-17ß-hydroxy-11-methylen-18,19-dinor-17alpha-pregn-4-en-20-yn-3-ons
DE19531936A1 (de) * 1995-08-17 1997-02-20 Schering Ag Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
WO1999067270A1 (en) 1998-06-19 1999-12-29 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
AU756739B2 (en) 1998-06-19 2003-01-23 N.V. Organon Testosterone derivative
US6180682B1 (en) 1999-01-26 2001-01-30 Virgil A. Place Buccal drug delivery system for use in male contraception
TW200400041A (en) * 2002-05-30 2004-01-01 Akzo Nobel Nv Use of new etonogestrel esters

Also Published As

Publication number Publication date
RS97604A (sr) 2006-10-27
IS2421B (is) 2008-10-15
WO2003102012A2 (en) 2003-12-11
NO20044898L (no) 2005-02-25
IL165087A0 (en) 2005-12-18
PL373855A1 (en) 2005-09-19
MXPA04011797A (es) 2005-03-31
NZ536619A (en) 2007-09-28
KR20050009723A (ko) 2005-01-25
ZA200410410B (en) 2006-02-22
DK1513861T3 (da) 2007-04-10
CA2487722A1 (en) 2003-12-11
ATE349458T1 (de) 2007-01-15
UA80126C2 (en) 2007-08-27
RU2004138807A (ru) 2005-05-27
AR040130A1 (es) 2005-03-16
ES2277085T3 (es) 2007-07-01
TW200403065A (en) 2004-03-01
HK1072609A1 (en) 2005-09-02
US7323454B2 (en) 2008-01-29
RU2325910C2 (ru) 2008-06-10
US20050222113A1 (en) 2005-10-06
JP4716726B2 (ja) 2011-07-06
BR0311254A (pt) 2005-03-15
PT1513861E (pt) 2007-03-30
EP1513861B1 (en) 2006-12-27
CO5631449A2 (es) 2006-04-28
EP1513861A2 (en) 2005-03-16
AU2003238081B2 (en) 2008-09-18
AU2003238081A1 (en) 2003-12-19
SI1513861T1 (sl) 2007-06-30
DE60310714D1 (de) 2007-02-08
WO2003102012A9 (en) 2005-01-13
HRP20041101A2 (en) 2004-12-31
CN1314701C (zh) 2007-05-09
JP2005532350A (ja) 2005-10-27
WO2003102012A3 (en) 2004-04-22
PE20040068A1 (es) 2004-02-18
CA2487722C (en) 2011-07-19
DE60310714T2 (de) 2007-10-11
CN1692122A (zh) 2005-11-02
IS7528A (is) 2004-11-15

Similar Documents

Publication Publication Date Title
CN101100480A (zh) 新颖的依托孕烯酯
JP3814292B2 (ja) エストラ−１，３，５（１０）−トリエン誘導体、これらの製造方法及びこれら化合物を含有する製薬組成物
JP2002518514A (ja) テストステロン誘導体
EP1513588B1 (en) Use of new etonogestrel esters
JPH0515720B2 (enExample)
HK1072609B (en) New etonogestrel esters
US3840568A (en) Estratriene derivatives
HK1072568B (en) Use of new etonogestrel esters
Ayerman A Synthetic Approach to Antiprogestational Steroids

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080109